IMTX250117P4000
- 0.00
- 0.000.00%
Immatics Newsroom
Is Immatics N.V. (IMTX) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround
Immatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
Immatics N.V.'s (NASDAQ:IMTX) Shares Lagging The Industry But So Is The Business
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $13
12 Health Care Stocks Moving In Friday's Pre-Market Session
Clear Street Launches Healthcare & Biotechnology Equity Research
Bristol Myers Squibb Terminates Agreements With Immatics Due To Ongoing Portfolio Prioritization Efforts Within BMS For Allogeneic Programs; Collaboration With BMS Under The 2019 Multi-Target TCR-T Strategic Collaboration Agreement Remains Ongoing
Mizuho Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $16
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
Goldman Sachs Initiates Immatics(IMTX.US) With Buy Rating, Announces Target Price $13.5
Earnings Update: Immatics N.V. (NASDAQ:IMTX) Just Reported And Analysts Are Boosting Their Estimates
Immatics Analyst Ratings
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $15
Jefferies Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Immatics(IMTX.US) With Buy Rating, Cuts Target Price to $15
Leerink Partners Maintains Immatics(IMTX.US) With Buy Rating, Announces Target Price $18
What Makes Immatics (IMTX) a New Buy Stock
Express News | Immatics NV : Piper Sandler Cuts Target Price to $18 From $19
Immatics Sees Revenue Surge Despite R&D Expenses